The Role of the Laboratory in the Diagnosis of LSD and Ecstasy Psychosis
Psychiatric Annals – March 01, 1994
Source: OpenAlex
Summary
Hallucinogens like Psilocybin, Ecstasy (MDMA), and Mescaline present a unique challenge: despite widespread substance abuse and availability, they are rarely identified in drug tests. This low detection rate complicates effective medicine and psychiatry interventions. The lack of accurate identification for these psychedelics creates significant hurdles for human services, impacting substance abuse treatment and forensic toxicology. This anomalous position demands attention for better outcomes.
Abstract
LSD and Ecstasy and other hallucinogenic drugs (especially psilocybin mescaline) are in an anomalous position as frequently abused, widely available illicit drugs that are rarely identified in drug tests.